Learn More
LBA4012 Background:Adjuvant chemomonotherapy in PAC results in five-year survival of 21% with median overall survival (mOS) of 23 months. Phase II trials evaluating adjuvant CRI showed promising(More)
4604 Background: To date, only limited toxicity data are available for the combination of erlotinib (E; 150 mg/d) with either gemcitabine (G) or capecitabine (C) as first-line therapy for advanced(More)
4047 Background: Within a cross-over phase III trial, we compared gemcitabine/erlotinib followed by capecitabine with capecitabine/erlotinib followed by gemcitabine in patients with treatment-naive(More)
  • 1